FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317877732> ?p ?o ?g. }

• W4317877732 endingPage "TPS814" @default.
• W4317877732 startingPage "TPS814" @default.
• W4317877732 abstract "TPS814 Background: Novel strategies are needed to improve immune responses in “cold” tumors such as pancreatic ductal adenocarcinoma (PDAC) and mismatch repair-proficient colorectal cancer (MMRp CRC). As a frequent oncogenic driver, mutant KRAS (mKRAS) neoantigens are attractive targets to augment anti-tumor immunity in both diseases. Recently, adoptive transfer of mKRAS G12D-specific T cells has shown durable tumor regressions in patients with metastatic CRC and PDAC (Tran et. al., 2020; Leidner et. al., 2022). Furthermore, our preclinical work has demonstrated that combining a mKRAS neoantigen vaccine with immune-modulating agents prevents progression of premalignant lesions to PDAC in mice (Keenan et. al., 2014). Based on this rationale, our study pairs a pooled synthetic long peptide (SLP) mKRAS vaccine with dual checkpoint blockade to assess safety and immunogenicity in patients with resected PDAC and chemorefractory MMRp CRC. Methods: This is a first-in-human, single-arm, open-label phase I trial evaluating a pooled SLP mKRAS vaccine combined with ipilimumab/nivolumab (ipi/nivo) in patients with resected PDAC (Cohort A, n = 12) and MMRp metastatic CRC (Cohort B, n = 12) The vaccine consists of poly-ICLC adjuvant admixed with SLPs corresponding to six common mKRAS subtypes: G12D, G12R, G12V, G12A, G12C, and G13D. In priming phase, the mKRAS vaccine is given on days 1, 8, 15, and 22 along with ipi/nivo. In boost phase, the mKRAS vaccine is given on weeks 13, 21, 29, 37, and 45 along with nivo alone. Cohort A patients who remain disease-free can continue to receive boost vaccines in a 12-month extended treatment phase. Eligible patients must have molecular tumor testing that demonstrates one of the six KRAS mutations listed above. Cohort A patients must be disease-free following completion of adjuvant chemotherapy within 6 months prior to study entry. Cohort B patients must have confirmed MMRp status, exposure to ≥ 2 prior lines of standard chemotherapy, and measurable disease amenable to biopsies at baseline and week 7. The co-primary endpoints of this study are safety and T cell response. Adverse events will be graded per NCI CTCAE v5.0. T cell response will be determined by the maximal percent change in IFNγ-producing mKRAS-specific T cell density within 16 weeks post-vaccination compared to baseline. Secondary endpoints include disease control and objective response rates at 16 weeks per RECIST v1.1/iRECIST (Cohort B only) as well as disease-free/progression-free and overall survival. Correlative studies will examine treatment-associated changes in T cell receptor (TCR) repertoire diversity by next-generation TCR sequencing of peripheral blood and tumor specimens. Patient accrual began in May 2020 and is completed for Cohort A. Enrollment is currently ongoing for Cohort B. Study drug support provided by Bristol Myers Squibb. Clinical trial information: NCT04117087 ." @default.
• W4317877732 created "2023-01-25" @default.
• W4317877732 creator A5010062331 @default.
• W4317877732 creator A5014073196 @default.
• W4317877732 creator A5015492234 @default.
• W4317877732 creator A5038721635 @default.
• W4317877732 creator A5050642902 @default.
• W4317877732 creator A5056139519 @default.
• W4317877732 creator A5060219345 @default.
• W4317877732 creator A5066065123 @default.
• W4317877732 creator A5071460094 @default.
• W4317877732 creator A5072177879 @default.
• W4317877732 creator A5080102032 @default.
• W4317877732 date "2023-02-01" @default.
• W4317877732 modified "2023-10-12" @default.
• W4317877732 title "A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer." @default.
• W4317877732 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.tps814" @default.
• W4317877732 hasPublicationYear "2023" @default.
• W4317877732 type Work @default.
• W4317877732 citedByCount "1" @default.
• W4317877732 crossrefType "journal-article" @default.
• W4317877732 hasAuthorship W4317877732A5010062331 @default.
• W4317877732 hasAuthorship W4317877732A5014073196 @default.
• W4317877732 hasAuthorship W4317877732A5015492234 @default.
• W4317877732 hasAuthorship W4317877732A5038721635 @default.
• W4317877732 hasAuthorship W4317877732A5050642902 @default.
• W4317877732 hasAuthorship W4317877732A5056139519 @default.
• W4317877732 hasAuthorship W4317877732A5060219345 @default.
• W4317877732 hasAuthorship W4317877732A5066065123 @default.
• W4317877732 hasAuthorship W4317877732A5071460094 @default.
• W4317877732 hasAuthorship W4317877732A5072177879 @default.
• W4317877732 hasAuthorship W4317877732A5080102032 @default.
• W4317877732 hasConcept C121608353 @default.
• W4317877732 hasConcept C126322002 @default.
• W4317877732 hasConcept C143998085 @default.
• W4317877732 hasConcept C147483822 @default.
• W4317877732 hasConcept C195616568 @default.
• W4317877732 hasConcept C203014093 @default.
• W4317877732 hasConcept C2776131300 @default.
• W4317877732 hasConcept C2776789287 @default.
• W4317877732 hasConcept C2777658100 @default.
• W4317877732 hasConcept C2777701055 @default.
• W4317877732 hasConcept C2777863537 @default.
• W4317877732 hasConcept C2778378633 @default.
• W4317877732 hasConcept C2780030458 @default.
• W4317877732 hasConcept C2780210213 @default.
• W4317877732 hasConcept C2780851360 @default.
• W4317877732 hasConcept C2781187634 @default.
• W4317877732 hasConcept C2781433595 @default.
• W4317877732 hasConcept C2994587330 @default.
• W4317877732 hasConcept C502942594 @default.
• W4317877732 hasConcept C526805850 @default.
• W4317877732 hasConcept C71924100 @default.
• W4317877732 hasConceptScore W4317877732C121608353 @default.
• W4317877732 hasConceptScore W4317877732C126322002 @default.
• W4317877732 hasConceptScore W4317877732C143998085 @default.
• W4317877732 hasConceptScore W4317877732C147483822 @default.
• W4317877732 hasConceptScore W4317877732C195616568 @default.
• W4317877732 hasConceptScore W4317877732C203014093 @default.
• W4317877732 hasConceptScore W4317877732C2776131300 @default.
• W4317877732 hasConceptScore W4317877732C2776789287 @default.
• W4317877732 hasConceptScore W4317877732C2777658100 @default.
• W4317877732 hasConceptScore W4317877732C2777701055 @default.
• W4317877732 hasConceptScore W4317877732C2777863537 @default.
• W4317877732 hasConceptScore W4317877732C2778378633 @default.
• W4317877732 hasConceptScore W4317877732C2780030458 @default.
• W4317877732 hasConceptScore W4317877732C2780210213 @default.
• W4317877732 hasConceptScore W4317877732C2780851360 @default.
• W4317877732 hasConceptScore W4317877732C2781187634 @default.
• W4317877732 hasConceptScore W4317877732C2781433595 @default.
• W4317877732 hasConceptScore W4317877732C2994587330 @default.
• W4317877732 hasConceptScore W4317877732C502942594 @default.
• W4317877732 hasConceptScore W4317877732C526805850 @default.
• W4317877732 hasConceptScore W4317877732C71924100 @default.
• W4317877732 hasFunder F4320308851 @default.
• W4317877732 hasFunder F4320332161 @default.
• W4317877732 hasFunder F4320332898 @default.
• W4317877732 hasIssue "4_suppl" @default.
• W4317877732 hasLocation W43178777321 @default.
• W4317877732 hasOpenAccess W4317877732 @default.
• W4317877732 hasPrimaryLocation W43178777321 @default.
• W4317877732 hasRelatedWork W1923854544 @default.
• W4317877732 hasRelatedWork W1963731933 @default.
• W4317877732 hasRelatedWork W2780485172 @default.
• W4317877732 hasRelatedWork W3157008565 @default.
• W4317877732 hasRelatedWork W4205416127 @default.
• W4317877732 hasRelatedWork W4211002554 @default.
• W4317877732 hasRelatedWork W4289107172 @default.
• W4317877732 hasRelatedWork W4292373623 @default.
• W4317877732 hasRelatedWork W4308181630 @default.
• W4317877732 hasRelatedWork W4317877732 @default.
• W4317877732 hasVolume "41" @default.
• W4317877732 isParatext "false" @default.
• W4317877732 isRetracted "false" @default.
• W4317877732 workType "article" @default.